Washington, D.C. 20549


Form 8-K



Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 19, 2011 (December 16, 2011)


Array BioPharma Inc.

(Exact name of registrant as specified in its charter)



(State or other jurisdiction

of incorporation)





File Number)


(I.R.S. Employer
Identification No.)


3200 Walnut Street, Boulder, Colorado



(Address of principal executive offices)


(Zip Code)



(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01


Other Events.


As previously announced, on December 16, 2011, Array BioPharma Inc. (“Array”) gave a presentation at an Analyst and Investor Day in New York City discussing previously announced results on its clinical programs in cancer and inflammation. Array also updated information on Array’s current expectations with respect to the timing of the announcement of certain clinical trial results and the completion of certain clinical trial milestones during 2012, which are set forth on the slide attached as Exhibit 99.1 attached to this Form 8-K and incorporated herein by reference.


Array BioPharma Forward-Looking Statement

This current report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the timing of the announcement of certain clinical trial results, the timing of the completion of certain clinical trial milestones and future plans to progress and develop Array’s proprietary and partnered programs. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements. We are providing this information as of December 19, 2011. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.


Item 9.01


Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.





Slide summarizing 2012 milestones






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: December 19, 2011

Array BioPharma Inc.







/s/ R. Michael Carruthers



R. Michael Carruthers



Chief Financial Officer






Exhibit No.








Slide summarizing 2012 milestones